Although EGFR-tyrosine kinase inhibitor (TKI) has low cerebrospinal fluid penetration rates [6], it may result in good intracranial response rates due to a high sensitivity of EGFR-mutant tumour to EGFR-TKI [7]. Here, EGFR is linked to neoplasm.